In this paper we report on the preliminary characterization of a mutant of herpes simplex virus type. 1 (HSV-1) selected for acycloguanosine (acyclovir, ACV) resistance in vitro. The ACV' virus was examined for a series of parameters that include chemosensitivity assay, thymidine kinase (TK) activit
An in vitro reactivation system for investigation of herpes simplex virus latency
β Scribed by C. S. Gunn; Dr. P. N. Goldwater
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 487 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
An in vitro reactivation system for investigation of herpes simplex virus latency which is inexpensive, simple, and convenient to establish and operate is presented. The system is useful for investigation of compounds that may be involved in suppression or augmentation of herpes simplex virus reactivation. The uses of this model in exploring the mechanism of HSV reactivation, in screening for drugs which affect this process, and in testing their mode of action are discussed.
π SIMILAR VOLUMES
MRL Diagnostics has developed a dual enzyme immunoassay (EIA) system that employs the recombinant Herpes Simplex Virus (HSV) type-specific glycoproteins G1 (HSV1) and G2 (HSV2) to detect HSV typespecific IgG antibodies. This system was evaluated using 155 consecutive sera previously tested in a conv
A series of 67 oligopeptides that spanned the open reading frame of herpes simplex virus type 2 (HSV-2) glycoprotein G (gG2) were synthesized and tested for reactivity with 173 serum specimens collected from 117 individuals. The oligopeptides were made as multiple antigenic peptides consisting of fo
It is critical to develop new therapies, such as gene therapy, which can impact on both local and metastatic prostate cancer progression. We have developed an orthotopic mouse model of metastatic prostate cancer using a cell line (RM-1) derived from the mouse prostate reconstitution (MPR) model syst